VKTX Stock Forecast: Viking Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Viking Therapeutics, Inc. is $95. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 13 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Viking Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (65): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VKTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VKTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 3 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Oct 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 Oct 2026 | Canaccord Genuity | Maintains | Buy | $106 → $118 |
| 20 Oct 2026 | Canaccord Genuity | Maintains | Buy | $114 → $106 |
| 15 Oct 2026 | UBS | Initiates | Buy | $94 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $87 → $85 |
| 23 Sept 2026 | Truist Securities | Maintains | Buy | $83 → $87 |
| 11 Aug 2026 | JP Morgan | Maintains | Overweight | $75 → $65 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $107 → $114 |
| 28 May 2026 | Lake Street | Initiates | Buy | $89 |
| 1 May 2026 | BTIG | Reiterates | Buy | — |
| 30 Apr 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 23 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 29 Oct 2025 | Canaccord Genuity | Initiates | Buy | — |
| 24 Oct 2025 | JP Morgan | Maintains | Overweight | — |
| 23 Oct 2025 | Morgan Stanley | Maintains | Overweight | — |
| 29 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Sept 2025 | BTIG | Reiterates | Buy | — |
| 19 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 July 2025 | Citigroup | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VKTX.
This page is one stock. Monday covers all of them.
VKTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VKTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Viking Therapeutics, Inc. returned −27.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VKTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 5.7×
- EV / EBITDA
- —
Cheaper than 15% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −96.4%
- Return on assets
- −47.2%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Viking Therapeutics, Inc. has a market value of $3.3B and an enterprise value of $2.6B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$534.8M.
Diluted earnings per share, trailing twelve months: −$4.66.
Free cash flow in the twelve months to 30 June 2026: −$418.4M.
Viking Therapeutics, Inc. employs 74 people.
Data provided by Twelve Data
VKTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VKTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Viking Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VKTX
What is the VKTX stock price forecast for 2026-2027?
The median 12-month analyst price target for Viking Therapeutics, Inc. is $95, with estimates ranging from $34 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VKTX stock a buy right now?
Of the 21 analysts covering Viking Therapeutics, Inc., 19 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viking Therapeutics, Inc. 13 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VKTX?
As at 21 Nov 2026, Viking Therapeutics, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (65 of 100).
Will VKTX stock go up?
No one can know that. What the data says: the median 12-month target from 21 analysts is $95, and Ticker Nerd's factor model ranks Viking Therapeutics, Inc. 13 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VKTX stock forecast for 2030?
No analyst covering Viking Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VKTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $125 over the next 12 months.
How has VKTX stock performed over the past year?
Viking Therapeutics, Inc. returned -27.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Viking Therapeutics, Inc. do?
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease. The company also works on VK0214 for X-linked adrenoleukodystrophy, VK5211 for recovery after hip fracture surgery, VK0612 for metabolic disorders and anemia, and VK3019, an amylin receptor agonist in early study. Based in San Diego, California, Viking Therapeutics is positioned as a research-focused drug developer addressing high-need areas across obesity, liver disease, rare disease, and other endocrine-related conditions.
CEO Dr. Brian Lian Ph.D. · 74 employees · United States · https://www.vikingtherapeutics.com